Tag:
Celgene
Latest Headlines
Latest Headlines
The biggest R&D spenders in biotech
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
TheStreet: A roundup of the top drug studies left in 2012
Any forward-looking student of the biotech industry will have to check out Adam Feuerstein's review in TheStreet of 22 Phase II and III clinical trials--21 drugs and one diagnostic test--which are expected to read out by the end of this year.
Three new rules for biopharma collaborations
Last week Ryan McBride moderated a panel called "The New Rules of Partnerships and Collaborations" at the Convergence East conference on Cape Cod, and the experience yielded a chance to probe some of the biopharma industry's top dealmakers about their preferences and prejudices going into talks with other companies.
Epizyme builds epigenetics lineup with $90M Celgene score
The pact includes a commitment to pay tens of millions more in milestones for any successful therapies that come out of the deal.
Double dose of deals as Celgene buys Avila, Amgen nabs Micromet
Celgene ( $CELG ) snapped up Avila Therapeutics and its early-stage Btk inhibitor in a "grand slam" buyout that could hit $925 million with milestone payments. And not to be left out of the day's
UPDATED: Celgene snaps up Avila Therapeutics in $925M buyout
In less than five years Avila Therapeutics nailed down a reputation as an exciting developer of covalent drugs, with a lead Btk inhibitor for cancer garnering attention at a very early stage of
Analysts tap Amgen, Celgene as potential 2012 dealmakers
Analysts are saying the world's biggest biotechs, including Amgen ( $AMGN ) and Celgene ( $CELG ), are likely to scout for big acquisitions this year as they seek to revive growth and refill pipelines,
Amgen, big biotechs poised for big year of deals, analysts say
It's always a safe bet that biotech's biggest players will be actively seeking mergers and other deals in any given year. Yet analysts tell Bloomberg that 2012 might be one in which heavy hitters
Celgene halts Revlimid trial in prostate cancer
Celgene's bid to expand use of Revlimid as a prostate cancer treatment just hit a major snag. The company stopped a Phase III trial after an independent monitoring committee determined that adding
Celgene halts Revlimid prostate cancer PhIII as survival trend falls short
Celgene's development plan for Revlimid has run into a brick wall of bad data. The biotech ( $CELG ) halted a late-stage study of the blockbuster drug for castration-resistant prostate cancer after an
